1. Kastner DL, Aksentijevich I, Goldbach-Mansky R: Autoinflammatory disease reloaded: A clinical perspective. Cell 140(6):784-790, 2010
2. The International FMF Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797-807, 1997
3. French FMF Consortium: A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25-31, 1997
4. McDermott MF et al: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97(1):133-144, 1999
5. Houten SM et al: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22(2):175-177, 1999
6. Drenth JP et al: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 22(2):178-181, 1999
7. Miceli-Richard C et al: CARD15 mutations in Blau syndrome. Nat Genet 29(1):19-20, 2001
8. Kanazawa N et al: Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: Common genetic etiology with Blau syndrome. Blood 105(3):1195-1197, 2005
9. Wise CA et al: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11(8):961-969, 2002
10. Hoffman HM et al: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29(3):301-305, 2001
11. Feldmann J et al: Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71(1):198-203, 2002
12. Aksentijevich I et al: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46(12):3340-3348, 2002
13. Goldbach-Mansky R: Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 1182:111-123, 2009
14. Aksentijevich I et al: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426-2437, 2009
15. Reddy S et al: An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 360(23):2438-2444, 2009
16. Ferguson PJ et al: Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 42(7):551-557, 2005
17. Ferguson PJ, El-Shanti HI: Autoinflammatory bone disorders. Curr Opin Rheumatol 19(5):492-498, 2007
18. Glocker EO et al: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361(21):2033-2045, 2009
19. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 449(7164):819-826, 2007
20. Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 11(5):373-384, 2010
21. Schroder K, Tschopp J: The inflammasomes. Cell 140(6):821-832, 2010
22. Masters SL et al: Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 27:621-668, 2009
23. McGonagle D et al: Management of treatment resistant inflammation of acute on chronic tophaceous gout with
anakinra.
Ann Rheum Dis 66(12):1683-1684, 2007
24. So A et al: A pilot study of IL-1 inhibition by
anakinra in acute gout.
Arthritis Res Ther 9(2):R28, 2007
25. Terkeltaub R et al: The interleukin 1 inhibitor
rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.
Ann Rheum Dis 68(10):1613-1617, 2009
26. Larsen CM et al: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517-1526, 2007
27. Botsios C et al: Resistant Behcet disease responsive to
anakinra.
Ann Intern Med 149(4):284-286, 2008
28. Pascual V et al: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479-1486, 2005
29. RLaRHA K: A case of cold urticaria with an unusual family history. JAMA 114:1067-1068, 1940
30. Muckle TJ: The ‘Muckle-Wells’ syndrome. Br J Dermatol 100(1):87-92, 1979
31. Prieur AM, Griscelli C: Arthropathy with eruption, chronic meningitis, eye lesions, and mental retardation. J Pediatr 99(1):79-83, 1981
32. Martinon F, Burns K, Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417-426, 2002
33. Gattorno M et al: Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 56(9):3138-3148, 2007
34. Lachmann HJ et al: In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 206(5):1029-1036, 2009
35. Goldbach-Mansky R et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581-592, 2006
36. Aksentijevich I et al: The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56(4):1273-1285, 2007
37. Saito M et al: Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 52(11):3579-3585, 2005
38. Hill SC et al: Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 37(2):145-152, 2007
39. Johnstone RF, Dolen WK, Hoffman HM: A large kindred with familial cold autoinflammatory syndrome. Ann Allergy Asthma Immunol 90(2):233-237, 2003
40. Tindall JP, Beeker SK, Rosse WF: Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med 124(2):129-134, 1969
41. Farasat S, Aksentijevich I, Toro JR: Autoinflammatory diseases: Clinical and genetic advances. Arch Dermatol 144(3):392-402, 2008
42. Hoffman HM, Wanderer AA, Broide DH: Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108(4):615-620, 2001
43. Lieberman A, Grossman ME, Silvers DN: Muckle-Wells syndrome: Case report and review of cutaneous pathology. J Am Acad Dermatol 39(2 Pt 1):290-291, 1998
44. Zip CM et al: Familial cold urticaria. Clin Exp Dermatol 18(4):338-341, 1993
45. Aganna E et al: Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46(9):2445-2452, 2002
46. Thornton BD et al: Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 49(3):477-481, 2007
47. Neven B, Prieur AM, Quartier dit Maire P: Cryopyrinopathies: Update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4(9):481-489, 2008
48. Hoffman HM et al: Efficacy and safety of
rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies.
Arthritis Rheum 58(8):2443-2452, 2008
49. Lachmann HJ et al: Use of
canakinumab in the cryopyrin-associated periodic syndrome.
N Engl J Med 360(23):2416-2425, 2009
50. Neven B et al: Long-term efficacy of the interleukin-1 receptor antagonist
anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Arthritis Rheum 62(1):258-267, 2010
51. Gensure RC et al: A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest 115(5):1250-1257, 2005
52. Leung VC, Lee KE: Infantile cortical hyperostosis with intramedullary lesions. J Pediatr Orthop 5(3):354-357, 1985
53. Ivker RA et al: Infantile generalized pustular psoriasis associated with lytic lesions of the bone. Pediatr Dermatol 10(3):277-282, 1993
54. Touitou I: The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 9(7):473-183, 2001
55. Majeed HA et al: Familial Mediterranean fever in children: The expanded clinical profile. Q J Med 92(6):309-318, 1999
56. Tunca M et al: Familial Mediterranean fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine (Baltimore) 84(1):1-11, 2005
57. Stoffman N et al: Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 8(4):307-310, 2000
58. Tunca M et al: The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. Eur J Hum Genet 10(12):786-789, 2002
59. Yilmaz E et al: Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9(7):553-555, 2001
60. Chae JJ et al: Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11(3):591-604, 2003
61. Booth DR et al: The genetic basis of autosomal dominant familial Mediterranean fever. Q J Med 93(4):217-221, 2000
62. Bernot A et al: Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum Mol Genet 7(8):1317-1325, 1998
63. Aksentijevich I et al: Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 64(4):949-962, 1999
64. Dode C et al: Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 92(4):241-246, 2000
65. La Regina M et al: Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet 11(1):50-56, 2003
66. Aldea A et al: The west side story: MEFV haplotype in Spanish FMF patients and controls, and evidence of high LD and a recombination “hot-spot” at the MEFV locus. Hum Mutat 23(4):399, 2004
67. Konstantopoulos K, Kanta A: Familial Mediterranean fever seems to be not uncommon in Greece. Eur J Hum Genet 12(2):85-86, 2004
68. Deltas CC et al: Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. Genet Test 6(1):15-21, 2002
69. Sohar E et al: Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43(2):227-253, 1967
70. Schwabe AD, Peters RS, Familial Mediterranean fever in armenians. analysis of 100 cases. Medicine (Baltimore) 53(6):453-462, 1974
71. Marek-Yagel D et al: Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 60(6):1862-1866, 2009
72. Booty MG et al: Familial Mediterranean fever with a single MEFV mutation: Where is the second hit? Arthritis Rheum 60(6):1851-1861, 2009
73. James LC et al: Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 104(15):6200-6205, 2007
74. Song B et al: Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 79(7):3930-3937, 2005
75. Perron MJ, Stremlau M, Sodroski J: Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. J Virol 80(11):5631-5636, 2006
76. Schaner P et al: Episodic evolution of pyrin in primates: Human mutations recapitulate ancestral amino acid states. Nat Genet 27(3):318-321, 2001
77. Centol M, Aksentijevich I, Kastner DL: The hereditary periodic fever syndromes: Molecular analysis of a new family of inflammatory diseases. Hum Mol Genet 7(10):1581-1588, 1998
78. Chae JJ et al: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 112(5):1794-1803, 2008
79. Mansfield E et al: The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98(3):851-859, 2001
80. Goldfinger SE:
Colchicine for familial Mediterranean fever.
N Engl J Med 287(25):1302
81. Chae JJ et al: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 103(26):9982-9987, 2006
82. Yu JW et al: Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 28(2):214-227, 2007
83. Richards N et al: Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 276(42):39320-39329, 2001
84. Padeh S et al: Familial Mediterranean Fever in the first two years of life: A unique phenotype of disease in evolution. J Pediatr 156(6):985-989, 2010
85. Zimand S et al: Familial Mediterranean fever presenting with massive cardiac tamponade. Clin Exp Rheumatol 12(1):67-69, 1994
86. Kees S et al: Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). Q J Med 90(10):643-647, 1997
87. Langevitz P et al: Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 21(9):1708-1709, 1994
88. Livneh A et al: Recurrent episodes of acute scrotum with ischemic testicular necrosis in a patient with familial Mediterranean fever. J Urol 151(2):431-432, 1994
89. Gedalia A, Zamir S: Neurologic manifestations in familial Mediterranean fever. Pediatr Neurol 9(4):301-302, 1993
90. Barzilai A et al: Erysipelas-like erythema of familial Mediterranean fever: Clinicopathologic correlation. J Am Acad Dermatol 42(5 Pt 1):791-795, 2000
91. Azizi E,Fisher BK: Cutaneous manifestations of familial Mediterranean fever. Arch Dermatol 112(3):364-366, 1976
92. Majeed HA et al: The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. Q J Med 75(278):607-616, 1990
93. Samuels J et al: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 77(4):268-297, 1998
94. Medlej-Hashim, M et al: Familial Mediterranean Fever: Association of elevated IgD plasma levels with specific MEFV mutations. Eur J Hum Genet 9(11):849-854, 2001
95. Tunca M et al: Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415, 1999
96. Lachmann HJ et al: Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746-750, 2006
97. Lachmann HJ et al: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361-2371, 2007
98. Livneh A et al: MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6(1):1-6, 1999
99. Saatci U et al: Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 82(8):705-706, 1993
100. Tinaztepe K et al: The association between Henoch-Schonlein syndrome and renal amyloidosis: A proposal of a pathogenic mechanism. Turk J Pediatr 35(4):249-256, 1993
101. Reidpath DD,Allotey P: Infant mortality rate as an indicator of population health. J Epidemiol Community Health 57(5):344-346, 2003
102. Touitou I et al: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56(5):1706-1712, 2007
103. Baba S et al: A novel allelic variant of serum amyloid A, SAA1 gamma: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4(6):1083-1087, 1995
104. Booth DR et al: SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 5(4):262-265, 1998
105. Wright DG et al: Efficacy of intermittent
colchicine therapy in familial Mediterranean fever.
Ann Intern Med 86(2):162-165, 1977
106. Kone-Paut I et al: The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford) 48(7):840-842, 2009
107. Zemer D et al: A controlled trial of
colchicine in preventing attacks of familial mediterranean fever.
N Engl J Med 291(18):932-934, 1974
108. Kuncl RW et al:
Colchicine myopathy and neuropathy.
N Engl J Med 316(25):1562-1568, 1987
109. Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 345(24):1748-1757, 2001
110. Hoffmann G et al: Mevalonic aciduria—An inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med 314(25):1610-1614, 1986
111. Schafer BL et al: Molecular cloning of human mevalonate kinase and identification of a missense mutation in the genetic disease mevalonic aciduria. J Biol Chem 267(19):13229-13238, 1992
112. Cuisset L et al: Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 9(4):260-266, 2001
113. van der Hilst JC et al: Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87(6):301-310, 2008
114. Houten SM et al: Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 11(2):196-200, 2003
115. Hoffmann GF et al: Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91(5):915-921, 1993
116. Hinson DD et al: Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry. Am J Hum Genet 65(2):327-335, 1999
117. Houten SM et al: Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 11(25):3115-3124, 2002
118. McTaggart SJ: Isoprenylated proteins. Cell Mol Life Sci 63(3):255-267, 2006
119. Frenkel J et al: Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46(10):2794-2803, 2002
120. Mandey SH et al: A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 54(11):3690-3695, 2006
121. Drenth JP, Haagsma CJ, van der Meer JW: Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73(3):133-144, 1994
122. Drenth JP et al: Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol 130(1):59-65, 1994
123. Boom BW et al: IgD immune complex vasculitis in a patient with hyperimmunoglobulinemia D and periodic fever. Arch Dermatol 126(12):1621-1624, 1990
124. Haraldsson A et al: Immunological studies in the hyper-immunoglobulin D syndrome. J Clin Immunol 12(6):424-428, 1992
125. Miyagawa S et al: Association of hyperimmunoglobulinaemia D syndrome with erythema elevatum diutinum. Br J Dermatol 128(5):572-574, 1993
126. Hinson DD et al: Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 78(5):408-412, 1998
127. Simon A et al:
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Clin Pharmacol Ther 75(5):476-483, 2004
128. Neven B et al: Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 356(26):2700-2703, 2007
129. Lindor M et al: A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72(7):611-615, 1997
130. Shoham NG et al: Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 100(23):13501-13506, 2003
131. Yeon HB et al: Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 66(4):1443-1448, 2000
132. Stichweh DS, Punaro M, Pascual V: Dramatic improvement of pyoderma gangrenosum with
infliximab in a patient with PAPA syndrome.
Pediatr Dermatol 22(3):262-265, 2005
133. Dierselhuis MP et al:
Anakinra for flares of pyogenic arthritis in PAPA syndrome.
Rheumatology (Oxford) 44(3):406-408, 2005
134. Brenner M et al: Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist
anakinra.
Br J Dermatol 161(5):1199-1201, 2009
135. Hull K.M et al: The TNF receptor-associated periodic syndrome (TRAPS): Emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81(5):349-368, 2002
136. Lainka E et al: Incidence of TNFRSF1A mutations in German children: Epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48(8):987-991, 2009
137. Sarrauste de Menthiere C et al: INFEVERS: The Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31(1):282-285, 2003
138. Touitou I et al: Infevers: An evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24(3):194-198, 2004
139. Milhavet F et al: The infevers autoinflammatory mutation online registry: Update with new genes and functions. Hum Mutat 29(6):803-808, 2008
140. Banner DW et al: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 73(3):431-445, 1993
141. Hull KM et al: The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 15(1):61-69, 2003
142. Ravet N et al: Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65(9):1158-1162, 2006
143. Aksentijevich I et al: The tumor-necrosis-factor receptor-associated periodic syndrome: New mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69(2):301-314, 2001
144. Aganna E et al: Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48(9):2632-2644, 2003
145. Lobito AA et al: Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108(4):1320-1327, 2006
146. Todd I et al: Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 56(8):2765-2773, 2007
147. Simon A et al: Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107(21):9801-9806, 2010
148. Jacobelli S et al: Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) 46(7):1211-1212, 2007
149. Nedjai B et al: Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(1):273-283, 2008
150. Nedjai B et al: Proinflammatory action of the antiinflammatory drug
infliximab in tumor necrosis factor receptor-associated periodic syndrome.
Arthritis Rheum 60(2):619-625, 2009
151. Stjernberg-Salmela S et al: Low TNF-induced NF-kappaB and p38 phosphorylation levels in leucocytes in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 49(2):382-390, 2010
152. Toro JR et al: Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. Arch Dermatol 136(12):1487-1494, 2000
153. Nakamura M, Kobayashi M, Tokura Y: A novel missense mutation in tumour necrosis factor receptor superfamily 1A (TNFRSF1A) gene found in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) manifesting adult-onset Still disease-like skin eruptions: Report of a case and review of the Japanese patients. Br J Dermatol 161(4):968-970, 2009
154. Hull K.M et al: Monocytic fasciitis: A newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46(8):2189-2194, 2002
155. Galon J et al: TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12(4):479-486, 2000
156. Drewe E et al: Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42(2):235-239, 2003
157. Weyhreter H et al: A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr 142(2):191-193, 2003
158. Lamprecht P et al: Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63(11):1518-1520, 2004
159. Gattorno M et al: Persistent efficacy of
anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.
Arthritis Rheum 58(5):1516-1520, 2008
160. Sacre K et al: Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35(2):357-358, 2008
161. Blau EB: Familial granulomatous arthritis, iritis, and eruption. J Pediatr 107(5):689-693, 1985
162. Jabs DA et al: Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 78(5):801-804, 1985
163. Rose C.D et al: Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 32(2):373-375, 2005
164. Rose CD et al: NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: Study of an international registry and a national cohort in Spain. Arthritis Rheum 60(6):1797-1803, 2009
165. Becker ML, Rose CD: Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 7(6):427-433, 2005
166. Hetherington S: Sarcoidosis in young children. Am J Dis Child 136(1):13-15, 1982
167. Inohara N, Nunez G: NODs: Intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 3(5):371-382, 2003
168. Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27(8):352-357, 2006
169. Priori R et al: Sporadic Blau syndrome with a double CARD15 mutation. Report of a case with lifelong follow-up. Sarcoidosis Vasc Diffuse Lung Dis 21(3):228-231, 2004
170. Rose CD et al: Pediatric granulomatous arthritis: An international registry. Arthritis Rheum 54(10):3337-3344, 2006
171. Arostegui JI et al: NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 56(11):3805-3813, 2007
172. Tilly JJ, Drolet BA, Esterly NB: Lichenoid eruptions in children. J Am Acad Dermatol 51(4):606-624, 2004
173. Kanazawa N, Furukawa F: Autoinflammatory syndromes with a dermatological perspective. J Dermatol 34(9):601-618, 2007
174. Schaffer JV et al: Widespread granulomatous dermatitis of infancy: An early sign of Blau syndrome. Arch Dermatol 143(3):386-391, 2007
175. Okafuji I et al: Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 60(1):242-250, 2009
176. Milman N et al: Favourable effect of TNF-alpha inhibitor (
infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation.
APMIS 114(12):912-919, 2006
177. Yasui K et al:
Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: Its possible action and mechanism.
Arthritis Rheum 62(1):250-257, 2010
178. Majeed HA et al: Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. J Pediatr 115(5 Pt 1):730-734
179. El-Shanti HI, Ferguson PJ: Chronic recurrent multifocal osteomyelitis: A concise review and genetic update. Clin Orthop Relat Res 462:11-19, 2007
180. Moore KW et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001
181. Kotenko SV et al: Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16(19):5894-5903, 1997
182. Kotenko SV et al: Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276(4):2725-2732, 2001
183. Sheppard P et al: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68, 2003
184. Kuhn R et al: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2):263-274, 1993